Fundraising Fox
Lincolnshire · Seed–Series A · 10 people tracked
Find your way into OMX Ventures
Sign up to see every warm intro you have to OMX Ventures
- Paths you didn't know you had: your email and LinkedIn already hold routes to the OMX Ventures team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
OMX Ventures takes a technology-first, first-principles approach, prioritizing groundbreaking solutions over established executive rosters. Leveraging a deep network of advisors, the firm seeks disruptive opportunities that others overlook and supports founders with focused research and valuable networks. It emphasizes deep technical and intellectual property expertise, working hands-on with founders to hit milestones, establish strong IP, and attract follow-on capital. The firm's supportive ecosystem is geared toward helping biological solutions grow into scalable companies.
Source: firm website, verified Sep 29, 2026.
Team · 10 people
from the firm's website & public directories
What they invest in
from 33 of 40 portfolio companiesBiotech ×31Deep Tech ×18Healthtech ×14Medical Devices ×12AI & Machine Learning ×9Digital Health ×5Hardware ×3AgTech ×1
HQs:United States×17United Kingdom×4
Who they back
founder profiles across 20 portfolio companiesFounding team size:solo founder×62 founders×53 founders×44+ founders×5
Where their founders studiedfrom 21 founders with education data
Massachusetts Institute of Technology ×7Stanford University ×3Princeton University ×2Stanford University School of Medicine ×2University of California, Berkeley ×2University of California, San Francisco ×2
What their founders studiedfrom 22 founders with field-of-study data
Engineering ×8Life Sciences ×8Chemistry ×5Computer Science ×3Business & Management ×2Mathematics & Statistics ×2Physics ×2
Accelerator rootsportfolio companies that came through a program
22 founders hold a PhD (of 22 with degree data)
Investments · 40 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 12024 · 42022 · 22021 · 22020 · 12019 · 22018 · 114 dated
10x Genomics offers single cell analysis technology, including its Flex assay and Flex Apex product, which use probe-based chemistry and plate-based multiplexing to profile fresh, frozen, and FFPE samples for researchers.
BiotechDeep TechHardwareHealthtechPleasanton, US
Serge Saxonov(Founder)inBen Hindson(Founder)inBrad Crutchfield(Chief Commercial Officer)Jean Philibert(Chief People Officer)Eric S Whitaker(General Counsel)inJustin McAnear(Chief Financial Officer)
Co-investorsFoothill VenturesForesite CapitalKhosla VenturesPaladin Capital GroupSoftBank Vision FundVenrock+4 more
Compass Pathways develops novel treatments for mental health conditions, with a focus on psychedelic-assisted therapies supported by rigorous clinical research.
BiotechDigital HealthHealthtechMedical DevicesMental Health
Kabir Nath(CEO)Ekaterina Malievskaia(Founder)George Goldsmith(Founder)
Co-investorsAble PartnersAisling CapitalBailey Venture PartnersCatalio Capital Management, LPNoeticVivo Capital+2 more
Ginkgo Bioworks builds autonomous labs that accelerate bioengineering for applications in pharmaceutical, agricultural, and industrial biotechnology.
AgTechAI & Machine LearningBiotechDeep TechHealthtechRoboticsBoston, US
Jason Kelly(Founder)inReshma Shetty(Founder)inBarry Canton(Founder)inAustin Che(Founder)inTom Knight(Founder)inBartholomew Canton(Executive Officer)
Co-investors11.2 CapitalAllen Institute for AI (AI2) IncubatorAzure Capital PartnersB3 HoldingBlue Owl CapitalCannage Capital+62 more
Twist Bioscience develops a silicon-based synthetic DNA manufacturing platform that produces high-quality DNA, genes, and NGS reagents for customers in medicine, agriculture, and industrial chemicals.
BiotechDeep TechSemiconductorsSouth San Francisco, US
William Charles Banyai(Executive Officer, Director, Promoter)Bill James Peck(Executive Officer, Promoter)Emily Leproust(Founder)inEmily Leproust, PhD(CEO and Co-Founder of Twist)Patrick Finn(President and Chief Operating Officer)inAdam Laponis(Chief Financial Officer)in
Co-investors+ND Capital3E Bioventures CapitalARCH Venture PartnersAsset Management CompanyATEL VenturesBay City Capital+10 more
Switchback Systems develops a benchtop DNA synthesis platform that combines onboard oligonucleotide synthesis and gene assembly, aimed at putting synthetic biology tools directly in scientists' hands.
BiotechDeep TechHardwareSan Francisco Bay Area, US
Mary Noe(Executive Officer, Director)in
BoardTimothy Richardson(Director)Paul Conley(Director)inA Craig Asher(Director)
Co-investorsAhren Innovation CapitalGENERAL INCEPTIONVertical Venture Partners
Aperiam Bio uses computer-vision algorithms to identify "hyperfolding" protein variants with improved expression, solubility, and stability, aiming for order-of-magnitude gains in protein performance.
AI & Machine LearningBiotechDeep TechAustin, US
Austin Cole(CEO & Founder)Guillaume Cottarel(Head of Program)inRussell Durrett(Chief Business Officer)
Co-investorsCivilization Ventures Management, LlcAxial VCKdT Ventures
BluumBio identifies and deploys naturally occurring enzymes from fungi, trees, and bacteria to remove industrial pollutants from soil, air, and water.
BiotechCleantechHealthtechImpact & Social GoodSan Francisco, US
Katherine French(Founder)inKathrine French(Founder)
Co-investorsCollaborative FundHAWKTAILOlive Tree CapitalOxonian VenturesY CombinatorAgrolimen Ventures+8 more
Cellsonics provides cell dissociation technology for research scientists using acoustic waveforms to isolate cells from tissue with higher biological relevance than conventional methods.
BiotechDeep TechHardwareMedical Devices
Co-investorsVertical Venture PartnersWavemaker Three-Sixty Health
Constructive Bio is a biotechnology company that rewrites the genetic code to give cells access to non-canonical amino acid building blocks, expanding the range of proteins that can be designed, engineered, and manufactured.
BiotechDeep TechNew MaterialsCambridge, GB
Jason Chin(Professor)Jason W. Chin(Founder)Julius Fredens(Founder)Ola Wlodek, PhD(CEO)Prof. Jason Chin, PhD(CSO & Founder)
Co-investors+ND CapitalAmadeus Capital PartnersFine Structures VenturesGENERAL INCEPTIONLongeVCPaladin Capital Group+2 more
Delix Therapeutics develops third-generation, non-hallucinogenic neuroplastogens for people with neurological conditions, using a discovery platform to identify novel compounds.
BiotechDigital HealthMedical Devices
David Olson(Founder)David Olson Nick Haft(Founder)Nick Haft(Founder)
Co-investorsArtis VenturesBailey Venture PartnersCasa Verde CapitalDolby Family VenturesNoeticPalo Santo VC+7 more
Develops novel ocular therapies.
BiotechMorrisville, US
Ben Yerxa(Executive Officer)inEric Linsley(Executive Officer)in
BoardEd Mathers(Director)inStephen Bloch(Director)inSeth Rudnick(Director)inNeal Fowler(Director)
Co-investorsCanaan PartnersNew Enterprise Associates (NEA)Pappas Capital+ND CapitalARCH Venture PartnersIllumina Ventures
Epana Bio develops therapies for autoimmune diseases by leveraging genomics and AI to identify and target cellular origins of disease, with a focus on precision medicine for patient populations.
AI & Machine LearningBiotechDigital Health
Co-investorsBreakout LabsBreakout VenturesHAWKTAILHummingbird VenturesPoint Financial CapitalKdT Ventures+2 more
Finch Therapeutics is a life sciences company focused on the development and protection of drug-related intellectual property and therapeutics within the biotechnology and pharmaceutical industry.
BiotechHealthtechMedical DevicesSomerville, US
Mark Smith(Executive Officer, Director)inMatt Blischak(Chief Executive Officer)inR. J. Price(Director)Jeffery A. Smisek(Director)Andrew Mulderry(Director)James Burgess(Director)
Co-investorsAvenir Growth CapitalB3 HoldingKleinmuntz AssociatesOctave Ventures LlcOCV PartnersShumway Capital+2 more
Freya Biosciences develops innovative therapies targeting immune-mediated diseases that affect women.
BiotechFemTechHealthtech
Colleen Acosta, PhD(CEO, Co-Founder)Johan van Hylckama Vlieg, PhD(CSO, Co-Founder)
Co-investorsAngelini VenturesIndaco Venture PartnersSofinnova PartnersBill & Melinda Gates Foundation
General Inception is an operational support and company building firm that handles day-to-day planning and execution for building companies, with a focus on life science tools and diagnostics.
Deep TechHealthtechMedical Devices
Co-investorsPaladin Capital GroupGenoa VenturesNorthpond VenturesVertical Venture Partners
Glyphic Biotechnologies develops ProSE™, a high-throughput de novo protein sequencing technology for analyzing proteomes with single-molecule sensitivity.
BiotechDeep TechBerkeley, US
Daniel Estandian(Founder)inEd Boyden(Founder)Josh Yang(Founder)inJoshua Yang(Founder)
BoardCraig Asher(Director)inJimmy Yun(Director)in
Co-investorsArtis VenturesBlack FlagCivilization Ventures Management, LlcFoundersX VenturesHarpoon VenturesIn-Q-Tel+9 more
BiotechBoulder, US
Michael Graige(Executive Officer)Ron McGrath(Executive Officer)Sri Kosaraju(Executive Officer, Director)Dianna L. DeVore(Executive Officer)Kevin Ness(Founder)Ryan Gill(Founder)
Co-investorsForesite CapitaliGlobe PartnersKorysOak HC/FTPaladin Capital GroupSpruce Capital Partners+4 more
Lightcast develops a single-cell functional analysis platform that uses droplet-based technology to profile cell function, biomolecule secretion, cell-cell interactions, and targeted cell killing at scale.
BiotechDeep TechHealthtech
Co-investors+ND CapitalIllumina VenturesLongwall Venture Partners LLPM VenturesARCH Venture Partners
Lightcast provides a next-generation single-cell functional analysis platform called Envisia that enables massively parallel profiling of cell-cell interactions and biomolecule secretion at scale.
BiotechDeep TechMedical DevicesCambridge, GB
Co-investorsARCH Venture PartnersIllumina VenturesPerscitus LLP+ND CapitalM Ventures
Matterworks builds foundation models (its Large Spectral Model, delivered via the cloud-based Pyxis platform) that analyze biochemical omics and mass spectrometry data to make predictions for life science R&D.
AI & Machine LearningBiotechDeep TechHealthtech
Jack (J.M.) Geremia(Founder)inEric Carlson, PhD
BoardTony KulesainMichael Lavinin
Co-investorsDYDX CapitalGermin8 VenturesiGlobe PartnersIntermountain HealthPillar VCWing+1 more
Overt Bio develops cell therapies that link genes to immune functions using genome-scale discovery platforms.
AI & Machine LearningBiotechMedical DevicesNew York, US
Dr. Legut(Co-Founder and CEO)Dr. Sanjana(Co-Founder)Mateusz Legut(Executive Officer, Director)Neville Sanjana(Director)Mat Legut(Founder)in
BoardVasudev Bailey(Director)in
Co-investorsArtis VenturesCivilization Ventures Management, LlcFusionHAWKTAILWingAlexandria+2 more
Reaxbio develops a chemoproteomics platform that identifies and targets novel protein sites for drug discovery across disease-relevant biological contexts.
AI & Machine LearningBiotechDeep Tech
Jeff Montgomery(Founder)in
Co-investorsPortal Innovations
Replay develops gene therapies for patients with rare genetic diseases.
BiotechHealthtechLongevity
Lachlan MacKinnon(CEO and Founder)Adrian Woolfson(Founder)Robert Coffin(Executive Chairman)Maria Castner-Miller(General Counsel)inRenata Martin(VP & Head of Gene Therapy)inSaurabh Sharma(VP & Head of CMC)
Co-investorsArtis VenturesSolari CapitalAxial VC
Stipple Bio develops targeted oncology therapies that act on tumor-specific cell surface epitopes to expand druggable targets and improve therapeutic index for cancer patients.
BiotechHealthtechCambridge, US
Aaron Ring(Co-founder)inAashish Manglik(Co-founder)inJeff Landau(Chief Executive Officer)inRoland Gendron(Chief Business Officer)inMichelle Zhang(Chief Scientific Officer)in
BoardVineeta Agarwala(Director)in
Co-investorsRA CapitalAndreessen HorowitzGV (Google Ventures)Magnetic VenturesAxial VCLoLa Capital Partners+1 more
Syndex develops mcPCR (methyl copying PCR), a proprietary platform technology that amplifies DNA while preserving methylation patterns, addressing the challenge of low DNA levels in clinical samples.
BiotechDeep TechMedical DevicesSanta Monica, US
Geoff Smith(Founder & CEO)inJason Betley(Chief Product Officer)in
Co-investors+ND CapitalARCH Venture Partners
Tagomics develops multimodal technologies for precision medicine and next-generation diagnostics.
AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, GB
Dr Jack Kennefick(Co-founder, Director & Chief Executive Officer)Dr Robert Neely(Co-founder, Director & Chief Scientific Officer)
Co-investorsCalculus Capital Ltd.Illumina VenturesIQ CapitalCalculusInnovate UKMEIF Proof-of-Concept & Early Stage Fund+2 more
.jpeg){kind=logo}
Tasso develops diagnostic testing devices and platforms for home use, enabling patients to perform health monitoring and inform clinical decisions outside traditional healthcare settings.
Digital HealthHealthtechMedical DevicesSeattle, US
Ben Casavant(Co-Founder and Chief Executive Officer)inErwin Berthier(Co-Founder and Chief Technology Officer)inAlan Levy(Director)
BoardElizabeth Hambrecht(Director)Paul Conley(Director)in
Co-investorsForesite CapitalJ2 VenturesMerck Global Health Innovation FundMSD Global Health Innovation FundRA CapitalTechstars+3 more
Tessera Therapeutics develops Gene Writing, a genome engineering technology platform designed to make permanent alterations to the human genome for treating diseases.
BiotechDigital HealthMedical Devices
Geoff von Maltzahn(Founder)inJoseph Romanelli(CEO)Geoffrey von Maltzahn(Founder)Jacob Rubens(Founder)Noubar Afeyan(Founder)Rob Citorik(Founder)
Co-investorsArtis VenturesFlagship PioneeringMarch Capital PartnersSoftBank Vision FundSolari CapitalToba Capital+5 more
SyntheX develops the ToRFLEx platform, a first-in-class drug discovery technology that enables screening for compounds that modulate protein-protein interactions and targeted protein degradation for previously inaccessible drug targets identified by geneticists.
AI & Machine LearningBiotechDeep Tech
Maria Soloveychik(PhD)in
Co-investorsNorth South VenturesThe Column Group8VC
Type6 Therapeutics is a drug-discovery company developing kinase inhibitors that target the inactive OFF-state of kinases to improve selectivity and durability against cancers that evade existing therapies.
BiotechDeep TechHealthtech
Gert Kiss(Co-founder & CEO)inAlexander Bridges(Co-founder, CSO, VP Chemistry)Jeffrey Ohren(Co-founder, VP Biology)inMihail Obrocea(Head of Development)Robert Sons(Head of Operations)
Co-investorsArtis VenturesBoxOne Ventures
VedaBio develops a molecular detection platform using CRISPR technology that enables rapid, accurate detection of multiple biological targets without the need for amplification.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesSan Diego, US
Anurup Ganguli(Founder)inFred(President and CEO)Frédéric Sweeney(President and Chief Executive Officer)inMaurice Exner(Chief Operating Officer)in
Co-investorsIllinois VenturesKleinmuntz AssociatesY CombinatorEvergreen Venture PartnersFox Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
1859CompassFinchSestinaSyntheXTARATARA BiosystemsType6Xeris
Exits · 4
4 IPOs10x GenomicsNASDAQ: TXGCompass PathwaysNASDAQ: CMPSGinkgo BioworksNYSE: DNATwist BioscienceNASDAQ: TWST
Portfolio news
latest coverage across their companies
Lightcast · finsmes.com · Apr 15, 2026
Matterworks · finsmes.com · Jun 3, 2025
Frequently asked questions
- How many investments has OMX Ventures made?
- OMX Ventures has 40 tracked investments, 4 of which have exited, including 2 dated in the last 24 months.
- What stage does OMX Ventures invest at?
- OMX Ventures invests at the Seed, Series A stages.
- What sectors does OMX Ventures focus on?
- OMX Ventures focuses on Biotech, Deep Tech, Healthtech, Medical Devices.
- Where is OMX Ventures located?
- OMX Ventures is headquartered in Lincolnshire, US.
- Does OMX Ventures lead rounds?
- OMX Ventures typically participates in rounds rather than leading them.
- Who does OMX Ventures co-invest with?
- OMX Ventures most often shares deals with Artis Ventures, Paladin Capital Group, iGlobe Partners, among 115 tracked co-investors.
Co-investors · 1
Northpond Ventures is a venture capital firm based in Bethesda, Maryland that invests in life sciences, technology, and related sectors.
Firms observed investing alongside OMX Ventures, from public investor directories. Shared companies are the overlap with OMX Ventures's recorded portfolio.
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Blackbird is a venture capital firm that backs founders from the earliest stages, with a focus on ambitious technology startups across Australia and New Zealand.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.